After 6 months of treatment, serum CXCL13 levels and SLEDAI were significantly decreased in the LN group (CXCL13: 258.86 [185.50–392.18] pg/mL versus 195.54 [165.98–233.01] pg/mL, resp.; Z = −2.59, P = 0.009; SLEDAI: 10 [8.75–12] versus 6 [4–6.5], Z = −2.56; P = 0.01). Here, CXCL13 is linked to lobular neoplasia.